Neurology

The FDA approved oveporexton for narcolepsy type 1 in adults, marking the first orexin receptor agonist targeting the underlying biological cause of narcolepsy.

The US FDA Fast Track status advances remlifanserin for Alzheimer disease psychosis, with phase 2 RADIANT data expected in fall 2026.

Ruth Benca, MD, PhD, and Adam Spira, PhD, discuss how sleep disturbances, especially sleep apnea, may drive dementia risk and what to ask patients.

FDA accepted Axsome’s NDA for AXS-12 for cataplexy in narcolepsy and set a PDUFA target action date of May 1, 2027.

Once-weekly subcutaneous lecanemab matched IV initiation exposure in early Alzheimer disease, but comparative clinical outcome data remain limited.

SLEEP 2026: A sleep expert discusses screening tools, referral pathways, and why sleep disorders matter for cardiometabolic health in primary care.

Tirzepatide, nerve stimulation, and oral AD109 are reshaping OSA care as phenotyping replaces the one-size-fits-all CPAP default.

Patients with OSA who cannot tolerate CPAP may benefit from discussions about oral appliances, HNS, and other treatment options. Sairam Parthasarathy, MD, dives deeper.

SLEEP 2026: Virend Somers, MD, PhD, details how busy primary care physicians can address sleep in routine visits.

SLEEP 2026: GLP-related home sleep testing made up 44% of primary care referrals, but many studies were negative or suboptimal, according to a late-breaking abstract.

SLEEP 2026: Virend Somers, MD, of Mayo Clinic, outlines why sleep has been added to the AHA's Life’s Essential 8.

Laura B. Herpel, MD, reviews REFRESH trial data on once-nightly oxybate in narcolepsy, focusing on daytime function, stimulant reduction, and mental health.

Patil reviews 3 new AASM guidelines at SLEEP 2026 covering updated CSA treatment, first-ever inpatient OSA guidance, and chronic insomnia therapy hierarchy.

Andrew Ho, MD, reviews single-center data showing GLP-1 coverage barriers reshaped OSA referral patterns, with symptom documentation absent in most cases.

SLEEP 2026: In an 8-week randomized trial, reishi mushroom extract reduced Insomnia Severity Index scores more than melatonin in adults with chronic insomnia.

Baker explains how smartwatch sleep data can open clinical conversations about menopausal sleep disturbance but emphasizes the importance of patient-reported outcomes.

SLEEP 2026: New long-term data showed pitolisant was generally well tolerated and improved symptoms in adults with idiopathic hypersomnia.

SLEEP 2026: Residual cataplexy affected 76.8% of treated adults with narcolepsy type 1 and was linked to greater symptom burden and poorer quality of life.

A 28-day smartwatch study in menopausal women found sleep fragmentation varied from night to night while total sleep time remained stable.

Wearable sleep tracker use was linked to better sleep in patients with insomnia and COMISA, while OSA showed a divergent pattern warranting further study.

Mander highlights sleep as a modifiable dementia risk factor, emphasizing sleep apnea diagnosis and treatment to support brain health.

Emerging data link sleep disorder severity to Alzheimer's biomarker accumulation, with small CPAP studies suggesting partial biomarker reversibility with treatment.

Prenatal sleep expectations predicted postpartum sleep quality above parity and psychiatric history, with postpartum anxiety further worsening outcomes.

Pauline Maki, PhD, reviews data showing over half of elinzanetant's sleep benefit in postmenopausal women is independent of VMS reduction.

From behavioral therapy to NK3 receptor antagonists, Baker outlines an expanding toolkit for menopausal sleep disturbance.